Strides Pharma’s arm gets USFDA’s tentative nod for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets

15 Sep 2023 Evaluate

Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global, Singapore, has received tentative approval for its New Drug Application (NDA) 505b2 of Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets from the United States Food & Drug Administration (USFDA). The Product will be manufactured at the company’s facility in Bengaluru.

Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa. The PEPFAR tentative approval for Strides qualifies the Company to participate in the PEPFAR programs that procure this lifesaving medicine. Through country tenders and donor funded programs it is estimated that the value of procurement for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets is $650 million.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.


Strides Pharma Scien Share Price

683.20 -1.10 (-0.16%)
23-Dec-2024 11:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.65
Dr. Reddys Lab 1350.30
Cipla 1482.65
Lupin 2184.20
Zydus Lifesciences 977.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.